{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:07:03Z","timestamp":1792638423603,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ctrv.2013.03.003","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T16:10:16Z","timestamp":1366128616000},"page":"966-973","source":"Crossref","is-referenced-by-count":34,"title":["Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone"],"prefix":"10.1016","volume":"39","author":[{"given":"Anna","family":"Pia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Arlt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Terzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2011.04.032","article-title":"The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature","volume":"60","author":"Sonpavde","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.beem.2008.10.014","article-title":"Genetics of congenital adrenal hyperplasia","volume":"23","author":"Krone","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"21","key":"10.1016\/j.ctrv.2013.03.003_b0020","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.03.003_b0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2013.03.003_b0030","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2174\/138945012803529956","article-title":"New perspectives in the therapy of castration resistant prostate cancer","volume":"13","author":"Rescigno","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ctrv.2013.03.003_b0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.steroids.2011.09.004","article-title":"Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies","volume":"76","author":"Gomez-Sanchez","year":"2011","journal-title":"Steroids"},{"issue":"8","key":"10.1016\/j.ctrv.2013.03.003_b0040","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/en.2010-0099","article-title":"The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals","volume":"151","author":"Hernandez-Diaz","year":"2010","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.ctrv.2013.03.003_b0045","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1096\/fj.09-147926","article-title":"The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure","volume":"24","author":"Nguyen Dinh Cat","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.ctrv.2013.03.003_b0050","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1096\/fj.06-7970com","article-title":"Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis","volume":"21","author":"Caprio","year":"2007","journal-title":"FASEB J"},{"issue":"9","key":"10.1016\/j.ctrv.2013.03.003_b0055","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/01.HYP.0000174329.99569.52","article-title":"Cardiovascular benefits of aldosterone receptors antagonists: what about potassium?","volume":"46","author":"Williams","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ctrv.2013.03.003_b0065","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","article-title":"Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development \u2013 A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone","volume":"109","author":"Keidar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ctrv.2013.03.003_b0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/er.2005-0004","article-title":"The nongenomic actions of aldosterone","volume":"26","author":"Funder","year":"2005","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.ctrv.2013.03.003_b0075","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"10.1016\/j.ctrv.2013.03.003_b0080","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/sal induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kydney Int"},{"issue":"8","key":"10.1016\/j.ctrv.2013.03.003_b0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ctrv.2013.03.003_b0090","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ctrv.2013.03.003_b0095","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.mce.2011.09.011","article-title":"The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism","volume":"350","author":"Marzolla","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"28","key":"10.1016\/j.ctrv.2013.03.003_b0105","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.beem.2008.09.009","article-title":"Therapeutic management of adrenal insufficiency","volume":"23","author":"Hahner","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ctrv.2013.03.003_b0115","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1530\/EJE-08-0874","article-title":"Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy","volume":"160","author":"Debono","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ctrv.2013.03.003_b0120","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1210\/jc.2008-2380","article-title":"Modified-release hydrocortisone to provide circadian cortisol profiles","volume":"94","author":"Debono","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/eci.11.95","article-title":"Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis","volume":"8","author":"Alten","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"14","key":"10.1016\/j.ctrv.2013.03.003_b0130","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ctrv.2013.03.003_b0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0031-1301281","article-title":"Primary aldosteronism: are we missing the wood for the trees","volume":"44","author":"Funder","year":"2012","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000209744","article-title":"Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review","volume":"30","author":"Bomback","year":"2009","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1016\/j.ctrv.2013.03.003_b0145","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ctrv.2013.03.003_b0150","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","article-title":"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture","volume":"31","author":"Luthy","year":"1988","journal-title":"J Steroid Biochem"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ardp.19953280211","article-title":"Synthesis and reactions of 2-methylene-canrenone","volume":"328","author":"Gorlitzer","year":"1995","journal-title":"Arch Pharmacol (Weinheim)"},{"issue":"14","key":"10.1016\/j.ctrv.2013.03.003_b0160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2013.03.003_b0165","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0091270005275894","article-title":"Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment","volume":"45","author":"Ravis","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ctrv.2013.03.003_b0170","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","article-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","volume":"72","author":"Richards","year":"2012","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.ctrv.2013.03.003_b0175","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2013.03.003_b0180","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.003_b0185","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2013.03.003_b0190","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.beem.2010.10.001","article-title":"Treatment of primary aldosteronism","volume":"24","author":"Quinkler","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2013.03.003_b0195","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralcorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ctrv.2013.03.003_b0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ctrv.2013.03.003_b0205","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2013.03.003_b0210","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ajpath.2012.06.009","article-title":"Evidence for steroidogenic potential in human prostate cell lines and tissues","volume":"181","author":"Bennett","year":"2012","journal-title":"Am J Pathol"},{"issue":"9427","key":"10.1016\/j.ctrv.2013.03.003_b0215","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(04)16503-3","article-title":"Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study","volume":"363","author":"Arlt","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ctrv.2013.03.003_b0220","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2013.03.003_b0225","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jpag.2010.08.018","article-title":"Pubertal delay, hypokalemia and hypertension caused by a rare form of congenital adrenal hyperplasia","volume":"24","author":"Olson","year":"2011","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"2","key":"10.1016\/j.ctrv.2013.03.003_b0230","first-page":"221","article-title":"Diagnosis and treatment of 17alpha-hydroxylase deficiency: a case report and literature review","volume":"40","author":"Zhang","year":"2008","journal-title":"Beijing Da Xue Xue Bao"},{"issue":"7","key":"10.1016\/j.ctrv.2013.03.003_b0235","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/09513591003632068","article-title":"17-alpha-Hydroxylase deficiency: a case report with clinical and molecular analysis","volume":"26","author":"Li","year":"2010","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"10.1016\/j.ctrv.2013.03.003_b0240","first-page":"843","article-title":"A case of 17 alpha-hydroxylase deficiency with male pseudohermaphroditism","volume":"56","author":"Taura","year":"1980","journal-title":"Nihon Naibunpi Gakkai Zasshi"},{"issue":"4","key":"10.1016\/j.ctrv.2013.03.003_b0245","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2265.2009.03636.x","article-title":"A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia","volume":"72","author":"Verma","year":"2010","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"1","key":"10.1016\/j.ctrv.2013.03.003_b0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study","volume":"161","author":"Johannsson","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ctrv.2013.03.003_b0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1210\/jc.2011-2036","article-title":"Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy","volume":"97","author":"Koetz","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ctrv.2013.03.003_b0260","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone","volume":"160","author":"L\u00f8v\u00e5s","year":"2009","journal-title":"Eur J Endocrinol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T13:00:09Z","timestamp":1562936409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737213000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0305737213000662"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}